CA3122261A1 - Methods of treating neurological and psychiatric disorders - Google Patents
Methods of treating neurological and psychiatric disorders Download PDFInfo
- Publication number
- CA3122261A1 CA3122261A1 CA3122261A CA3122261A CA3122261A1 CA 3122261 A1 CA3122261 A1 CA 3122261A1 CA 3122261 A CA3122261 A CA 3122261A CA 3122261 A CA3122261 A CA 3122261A CA 3122261 A1 CA3122261 A1 CA 3122261A1
- Authority
- CA
- Canada
- Prior art keywords
- disorder
- patient
- compound
- adverse events
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862776247P | 2018-12-06 | 2018-12-06 | |
| US62/776,247 | 2018-12-06 | ||
| US201962829796P | 2019-04-05 | 2019-04-05 | |
| US62/829,796 | 2019-04-05 | ||
| PCT/US2019/064646 WO2020118032A1 (en) | 2018-12-06 | 2019-12-05 | Methods of treating neurological and psychiatric disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3122261A1 true CA3122261A1 (en) | 2020-06-11 |
Family
ID=69024675
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3122261A Pending CA3122261A1 (en) | 2018-12-06 | 2019-12-05 | Methods of treating neurological and psychiatric disorders |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US20200179336A1 (https=) |
| EP (1) | EP3890726A1 (https=) |
| JP (2) | JP2022511509A (https=) |
| KR (1) | KR20210100667A (https=) |
| CN (2) | CN118576586A (https=) |
| AU (2) | AU2019394956B2 (https=) |
| CA (1) | CA3122261A1 (https=) |
| MX (1) | MX2021006553A (https=) |
| WO (1) | WO2020118032A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201510665WA (en) | 2009-12-04 | 2016-01-28 | Sunovion Pharmaceuticals Inc | Multicycle Compounds And Pharmaceutical Compositions Useful For The Treatment Of Neurological Disorders |
| MA45795A (fr) | 2016-07-29 | 2019-06-05 | Sunovion Pharmaceuticals Inc | Composés et compositions, et utilisations associées |
| MX390141B (es) | 2017-02-16 | 2025-03-20 | Sunovion Pharmaceuticals Inc | Metodos para tratar esquizofrenia |
| CA3070993C (en) | 2017-08-02 | 2025-05-20 | Sunovion Pharmaceuticals Inc. | ISOCHROMANE COMPOUNDS AND THEIR USES |
| UA130249C2 (uk) | 2018-02-16 | 2025-12-31 | Сумітомо Фарма Америка, Інк. | Солі, кристалічні форми і способи їх отримання |
| CA3180115A1 (en) | 2020-04-14 | 2021-10-21 | Sunovion Pharmaceuticals Inc. | (s)-(4,5-dihydro-7h-thieno[2,3-c]pyran-7-yl)-n-methylmethanamine for treating neurological and psychiatric disorders |
| US20220165391A1 (en) * | 2020-11-25 | 2022-05-26 | Kyndryl, Inc. | Multi-stage treatment recommendations |
| AU2022348905A1 (en) | 2021-09-23 | 2024-04-11 | Sumitomo Pharma America, Inc. | Methods of treating metabolic disorders |
| CA3260160A1 (en) | 2022-08-30 | 2024-03-07 | Sumitomo Pharma America, Inc. | ULOTARONT FOR THE ADJUVANT TREATMENT OF MAJOR DEPRESSIVE DISORDER |
| AU2023358704A1 (en) | 2022-10-13 | 2025-05-29 | Sumitomo Pharma America, Inc. | Methods of reducing physical dependence to neuropsychiatric treatments |
| KR20250088777A (ko) | 2022-10-28 | 2025-06-17 | 스미토모 파마 아메리카, 인크. | 불안 및 연관된 상태를 치료하기 위한 울로타론트 |
| WO2024107681A1 (en) | 2022-11-15 | 2024-05-23 | Sumitomo Pharma America, Inc. | Methods of switching neuropsychiatric medications using ulotaront |
| CN115754079B (zh) * | 2022-11-28 | 2025-04-04 | 合肥和合医疗科技有限公司 | 一种同时检测7种精神药物及其代谢产物含量的方法 |
| CN117594119B (zh) * | 2024-01-17 | 2024-05-10 | 北京大学第六医院 | 用于预测帕罗西汀或其药用盐对抑郁或焦虑症患者疗效的装置 |
| WO2025252814A1 (en) | 2024-06-04 | 2025-12-11 | Duc Duy Vo | Methods for treating trace amine-associated receptor 1 (taar1)-associated diseases or disorders comprising administration of novel taar1 agonists or pharmaceutical compositions thereof |
| WO2026015878A1 (en) * | 2024-07-12 | 2026-01-15 | Mindx Therapeutics, Inc. | A new combination therapy for treatment-resistant depression in patients with co-morbid metabolic syndrome |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201510665WA (en) | 2009-12-04 | 2016-01-28 | Sunovion Pharmaceuticals Inc | Multicycle Compounds And Pharmaceutical Compositions Useful For The Treatment Of Neurological Disorders |
| MX390141B (es) * | 2017-02-16 | 2025-03-20 | Sunovion Pharmaceuticals Inc | Metodos para tratar esquizofrenia |
| UA130249C2 (uk) | 2018-02-16 | 2025-12-31 | Сумітомо Фарма Америка, Інк. | Солі, кристалічні форми і способи їх отримання |
| JP2021513972A (ja) * | 2018-02-16 | 2021-06-03 | サノビオン ファーマシューティカルズ インクＳｕｎｏｖｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． | 社会的機能障害の治療方法 |
-
2019
- 2019-12-05 US US16/704,202 patent/US20200179336A1/en not_active Abandoned
- 2019-12-05 KR KR1020217020606A patent/KR20210100667A/ko not_active Ceased
- 2019-12-05 WO PCT/US2019/064646 patent/WO2020118032A1/en not_active Ceased
- 2019-12-05 CN CN202410509785.9A patent/CN118576586A/zh active Pending
- 2019-12-05 AU AU2019394956A patent/AU2019394956B2/en active Active
- 2019-12-05 MX MX2021006553A patent/MX2021006553A/es unknown
- 2019-12-05 JP JP2021531942A patent/JP2022511509A/ja active Pending
- 2019-12-05 EP EP19828449.9A patent/EP3890726A1/en active Pending
- 2019-12-05 CN CN201980087996.5A patent/CN113271936A/zh active Pending
- 2019-12-05 CA CA3122261A patent/CA3122261A1/en active Pending
-
2024
- 2024-02-01 US US18/429,524 patent/US20240350453A1/en not_active Abandoned
- 2024-11-15 JP JP2024199397A patent/JP2025024102A/ja active Pending
-
2025
- 2025-01-08 US US19/013,028 patent/US20250312308A1/en active Pending
- 2025-08-06 AU AU2025213591A patent/AU2025213591A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2025213591A1 (en) | 2025-08-21 |
| JP2022511509A (ja) | 2022-01-31 |
| AU2019394956A1 (en) | 2021-06-17 |
| KR20210100667A (ko) | 2021-08-17 |
| US20240350453A1 (en) | 2024-10-24 |
| US20250312308A1 (en) | 2025-10-09 |
| WO2020118032A1 (en) | 2020-06-11 |
| MX2021006553A (es) | 2021-09-08 |
| US20200179336A1 (en) | 2020-06-11 |
| JP2025024102A (ja) | 2025-02-19 |
| EP3890726A1 (en) | 2021-10-13 |
| CN118576586A (zh) | 2024-09-03 |
| AU2019394956B2 (en) | 2025-05-08 |
| CN113271936A (zh) | 2021-08-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250312308A1 (en) | Methods of treating neurological and psychiatric disorders | |
| EP4135690B1 (en) | (s)-(4,5-dihydro-7h-thieno[2,3-c]pyran-7-yl)-n-methylmethanamine for treating, preventing and/or managing a neurological and/or psychiatric disorder | |
| RU2757221C2 (ru) | Фармацевтические композиции, содержащие антипсихотическое лекарственное средство и ингибитор vmat2, и их применение | |
| AU2018201060B2 (en) | 7,8-dihydoxyflavone and 7,8-substituted flavone derivatives, compositions, and methods related thereto | |
| US12161623B2 (en) | Nonracemic mixtures and uses thereof | |
| CN114340670B (zh) | T-型钙通道调节剂的制剂及其使用方法 | |
| US11160758B2 (en) | Modified release formulations and uses thereof | |
| UA122780C2 (uk) | Композиції, що містять 2-((1-(2-(4-фторфеніл)-2-оксоетил)піперидин-4-іл)метил)ізоіндолін-1-он, для лікування шизофренії | |
| MX2008000250A (es) | Combinaciones de eszopiclona y trans-4-(3,4-diclorofenil)-1,2,3,4- tetrahidro-n-metil-1-naftalenamina o trans 4-(3,4-diclorofenil)-1, 2,3,4-tetrahidro-1-naftalenamina y metodos de tratamiento de menopausia y trastornos del estado de animo, ansiedad y | |
| JP2009500420A (ja) | エスゾピクロン及びｏ−デスメチルベンラファキシンの組み合わせ、並びに閉経期並びに気分、不安、及び認知障害の治療方法 | |
| HK40057761A (en) | Methods of treating neurological and psychiatric disorders | |
| JP2022087834A (ja) | 放出調節製剤およびその使用 | |
| HK40064212A (en) | Modified release formulations and uses thereof | |
| HK1119078A (en) | Combinations of eszopiclone and o-desmethylvenlafaxine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20231204 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241203 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241203 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241203 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20241209 |
|
| B12 | Application deemed to be withdrawn, abandoned or lapsed |
Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION Effective date: 20250409 |
|
| R11 | Change to the name of applicant or owner or transfer of ownership requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R11-R127 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER RECORDAL REQUEST OR RESPONSE Effective date: 20250911 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250911 |
|
| R14 | Transfer of ownership recorded |
Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R14-R129 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250925 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251028 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251028 |
|
| C11 | Application revival requested |
Free format text: ST27 STATUS EVENT CODE: N-6-6-C10-C11-C106 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REINSTATEMENT REQUEST RECEIVED Effective date: 20260407 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: N-6-6-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20260407 |